JPRN-UMIN000020607
Completed
未知
Efficacy and long-term safety trials - Double-blind, placebo-controlled, dose-response, parallel-group study using a test food "EMFCTR-01" of the usual dose or the triple dose - - Efficacy and long-term safety trials - Double-blind, placebo-controlled, dose-response, parallel-group study using a test food "EMFCTR-01" of the usual dose or the triple dose
Medical Fusion Co.,Ltd.0 sites45 target enrollmentJanuary 18, 2016
ConditionsHealthy person
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Healthy person
- Sponsor
- Medical Fusion Co.,Ltd.
- Enrollment
- 45
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •The following exclusion criteria apply to subjects. \-Use of any prescription drugs or any over\-the\-counter drugs from \-7 day to \-1 day before dosing. \-A person who have used the steroid drug within the past three months of consent acquisition date. \-A person with diseases of the digestive tract, liver, kidney, heart, and circulatory system that might affect test food absorption, distribution, metabolism, and excretion. \-A person with a lengthy surgical history, including gastrointestinal suture surgery, or intestinal resection. However, polypectomy and appendectomy will not exclude a patient. \-A person with a history of cerebrovascular disease (asymptomatic lacunar infarction is excluded). \-A person with tattoo. \-A person with hypersensitivity or idiosyncrasy, such as food allergies. \-A person with alcohol or drug dependency. \-A person who has participated in other clinical trials within 84 days of giving informed consent. \-A person who has donated 400 ml of blood within 84 days, 200 ml of blood within 28 days, or a blood component (plasma or platelets) within 14 days of giving informed consent. \-The person who hopes for pregnancy or the person who can't prevent conception during the clinical study. \-Nursing or pregnant woman. \-A person whose diagnosis requires treatment of mental illness by a clinical investigator. \-A person who housemate is participating or a plan to participate in this clinical study. \-A person with taking "tenshi no Lara" within the past for 1 year from an agreement acquisition day. \-A women who is postmenopausal \-A person who are engaged in night duty. \-The person doing the hair dyeing, the permanent wave and the frizzled hair correction, etc. which have an influence on a hair and scalp. \-A person who is unable to comply with administrative matters during the clinical study. \-A person who are determined ineligible by the clinical investigator.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Efficacy trial and long-term safety confirmation test- Efficacy and long-term safety of the test food TK61406 ingested as a single dose, in a double-blind, parallel-group comparison to placebo.A range of individuals from healthy to borderline conditions- Persons with tendency for constipation or diarrhea- Persons classified as normal to 1 degree of obesity- Persons classified with normal to 1 degree of average blood pressureJPRN-jRCT1091220210Tokai Pickling Co.,Ltd. Yasufumi Ohba, Masataka Fujita, Mitsuru Satsukawa, Tetsuhiro Kawamoto, Mika Komura, Shoko Nishio, Tetsuya Iyoda,Hiroshi Ono30
Recruiting
Phase 1
Short-term and long-term efficacy and safety evaluation of acupoint catgut embedding in the simple obesity: a randomized controlled double-blind trialITMCTR2200005494The Fifth Affiliated Hospital of Southern Medical University
Recruiting
Not Applicable
Evaluate the medicinal effects of both Ayurveda combinations Bio-Immune as Anti-viral and Covalix Vaccoil as alternate to Vaccine of COVID-19 on exposed individuals and Covid19 contact.Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereCTRI/2020/08/027084eaf BioLab Leaf Research Institute A Unit of Young Naturalist Network
Active, not recruiting
Phase 1
A follow-on study in patients who have received gene therapy for Beta-thalassemia in the TIGET-BTHAL study to assess safety and effectiveness of treatment.Beta-thalassemiaMedDRA version: 20.1Level: LLTClassification code 10054660Term: Thalassemia betaSystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2017-001366-14-ITGLAXOSMITHKLINE RESEARCH AND DEVELOPMENT10
Active, not recruiting
Phase 1
A long-term study to monitor the health status of people with cystic fibrosis who took part in a previous study with BI 3720931 (LenticlairTM-ON)Cystic fibrosisMedDRA version: 20.0Level: PTClassification code: 10011763Term: Cystic fibrosis lung Class: 100000004850Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]CTIS2023-504909-37-00Boehringer Ingelheim International GmbH27